Campbell & CO Investment Adviser LLC Purchases Shares of 26,996 Castle Biosciences, Inc. $CSTL

Campbell & CO Investment Adviser LLC acquired a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 26,996 shares of the company’s stock, valued at approximately $615,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CSTL. Schroder Investment Management Group increased its position in Castle Biosciences by 8.6% in the second quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock worth $13,198,000 after purchasing an additional 51,483 shares during the last quarter. Advisors Capital Management LLC grew its stake in shares of Castle Biosciences by 21.9% in the 2nd quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock worth $5,021,000 after buying an additional 44,180 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Castle Biosciences by 29.1% in the 2nd quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after buying an additional 28,359 shares during the last quarter. Braidwell LP raised its position in shares of Castle Biosciences by 125.3% during the 2nd quarter. Braidwell LP now owns 822,735 shares of the company’s stock valued at $16,800,000 after buying an additional 457,488 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Castle Biosciences by 6.2% in the 2nd quarter. Geode Capital Management LLC now owns 689,926 shares of the company’s stock valued at $14,090,000 after acquiring an additional 40,073 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 4,693 shares of Castle Biosciences stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $35.58, for a total transaction of $166,976.94. Following the completion of the sale, the insider directly owned 84,595 shares of the company’s stock, valued at $3,009,890.10. The trade was a 5.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Kristen M. Oelschlager sold 14,888 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total value of $585,247.28. Following the completion of the sale, the chief operating officer owned 12,323 shares of the company’s stock, valued at $484,417.13. This represents a 54.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 53,442 shares of company stock worth $1,826,797. Company insiders own 6.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CSTL shares. Guggenheim boosted their price objective on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. BTIG Research boosted their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Canaccord Genuity Group raised their price target on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. Finally, Lake Street Capital increased their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Castle Biosciences presently has an average rating of “Moderate Buy” and an average price target of $46.00.

Castle Biosciences Stock Up 0.3%

Shares of CSTL opened at $40.98 on Thursday. The firm has a fifty day moving average price of $38.86 and a 200-day moving average price of $28.02. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.20 billion, a P/E ratio of -91.07 and a beta of 1.06. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $42.17.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The company had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. Equities research analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.